Polmacoxib |
Catalog No.GC18271 |
Le polmacoxib (CG100649) est un anti-inflammatoire non stéroÏdien (AINS) actif par voie orale, premier de sa catégorie, qui est un double inhibiteur de la COX-2 (IC50 d'environ 0,1 μg/ml) et de l'anhydrase carbonique. Le polmacoxib inhibe l'adénome colorectal et la croissance tumorale dans des modèles murins.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 301692-76-2
Sample solution is provided at 25 µL, 10mM.
Polmacoxib is an inhibitor of cyclooxygenase 2 (COX-2) and the carbonic anhydrase subtypes I (CAI) and CAII. It inhibits COX-2 in the absence of carbonic anhydrase II with an IC50 value of 40 nM, which increases by approximately 4- and 17-fold in the presence of a CAII at a molar ratio of 1:1 and 1:5, respectively. It also inhibits CAI and CAII (IC50s = 210 and 95 nM, respectively). Polmacoxib prevents >95 and 90% of prostaglandin E2 (PGE2) production in HCA-7 and HT-29 human colon cancer cells, respectively, using concentrations of 0.01 and 0.001 ug/ml. It inhibits polyp formation in a transgenic mouse model of intestinal polyp formation and tumor growth in human colorectal carcinoma mouse xenograft models when used at a dose of 7 mg/kg. The inhibition of COX-2 and CAII by polmacoxib has the potential for fewer serious systemic adverse effects, including cardiovascular events associated with COX-2 selective inhibitors such as celecoxib . Formulations containing polmacoxib have been used in the treatment of osteoarthritis.
Review for Polmacoxib
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)Review for Polmacoxib
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *